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Summary 
To investigate the polymorphism of human minor histocompatibility  (mH) antigens, PBLs from 
23 Japanese individuals and 25 German individuals with HLA-B35 were studied by using four 
human mH antigen-specific,  HLA-B35-restricted  CTL clones. The CTL clones killed PHA- 
stimulated  PBLs from all 23 Japanese individuals. On the other hand,  they killed the PHA- 
stimulated PBLs from 19 of 25 German individuals and partially killed the PHA-stimulated PBLs 
from three German individuals (CTL weakly sensitive cell line); those from another three indi- 
viduals (CTL-resistant cell line) were not killed by the CTL clones. All of three CTL weakly 
sensitive cell lines carry HLA-B*3503 molecules, whereas the three CTL-resistant cell lines carry 
HLA-B*3502,  B'3507,  and B'3508 molecules. The cytotoxicity of the CTL clones for three 
CTL weakly sensitive cell lines was enhanced by stimulation of human mH peptides isolated 
from HLA-B*3501 molecules purified from CIR.-B*3501 cells. Small amounts of human mH 
peptides were isolated from B'3503 molecules purified from these three CTL weakly sensitive 
cell lines. Taken together, these results indicate that weak recognition by the CTL clones of 
three CTL weakly sensitive cell line results from a small amount of the human mH peptides 
presented by B'3503 molecules. The CTL-resistant cell line carrying B'3507 loaded with the 
human mH peptides was killed by four CTL clones, whereas the cell lines carrying B'3502 
or B'3508 loaded with the peptides were not. The human mH peptides were not isolated from 
B'3507 molecules purified from the cell lines expressing this subtype, whereas small amounts 
of the human mH peptides were isolated from B'3502  and B'3508 molecules purified from 
the cell lines expressing these subtypes. These results indicate that failure of the CTL recognition 
of the cell line carrying B'3507 is due to a lack of human mH antigens in this cell line. The 
failure of the CTL recognition of the cell lines carrying B'3502 and B'3508 is not explained 
by only the amount of the human mH peptides binding to these B35 subtype molecules because 
the amount of the human mH peptides eluted from B* 3502 and B'3508 molecules purified from 
the cell lines carrying these B35 subtypes is almost the same as that eluted from B'3503 mole- 
cules purified from the cell lines carrying B'3503. It is suspected that the conformational struc- 
ture of the human mH peptides bound to these HLA-B35 subtype molecules changes and in- 
itiates a lack of the recognition of the CTL clones. The currrent study showed that the human 
mH antigens  are conserved beyond race and that recognition by human mH antigen-specific 
T  cells is critically influenced by the subtypes of HLA class I molecules. 
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inor  histocompatibility  (mH) 1  antigens  have  not 
. been studied in detail  even though they are very im- 
portant  in  transplantation,  since  incompatibility  of these 
antigens induces the rejection of grafts in organ transplanta- 
tion and graft versus host disease in bone marrow transplan- 
tation (1). In these diseases, mH-specific cytotoxic T cells but 
not specifc antibodies are induced (2-7).  T  cells recognize 
mH antigens in association with MHC antigens (4,  5,  7). 
Recent  studies  have  demonstrated  that  mH  antigens  are 
presented as peptides by MHC class I molecules in the mouse 
(8-10)  and human (11-13). 
It is suspected  that mH peptides are derived from self- 
proteins or endogenously integrated viral  protein, and the 
peptides are transported into the endoplasmic reticulum via 
transporters after they are generated in the cytoplasm as pep- 
tides derived from self-proteins  and viral proteins (14-19). 
Peptides take part in the assembly of MHC class I molecules 
in the endoplasmic reticulum (20, 21). Assembled MHC class 
I molecules are transported to the cell surface and are recog- 
nized by T  cells. 
In the mouse '~50 mH antigen genes have been mapped 
using congenic strains, and a limited polymorphism is known 
(1). In contrast, genes encoding human mH antigens have 
not been mapped, and the polymorphism of human mH an- 
tigens is not known. A recent study of population genetics 
using HLA-A2-restricted human mH antigen-specific CTL 
clones (22) has shown that the phenotype frequencies of three 
human mH antigens are 69,  16,  and 7%. 
There are many HLA subtypes that are distinguished by 
alloreactive  CTL clones,  biochemical analysis  using  two- 
dimensional electrophoresis,  or molecular analysis using se- 
quencing of the genes encoding HLA antigens.  For example, 
12 subtypes of HLA-A2 have been reported. Only three of 
these subtypes can be distinguished by serology (23). Since 
amino acid substitutions found among the subtypes affect 
the presentation of virus antigens to specific T cells (24-28), 
it is assumed that a given subtype of HLA class I antigen 
cannot present human mH peptides to specific T cells. Thus, 
population genetic analysis using mere recognition by CTL 
clones may not reflect the frequencies  of mH antigens in a 
given population. 
To investigate phenotype frequencies  of human mH an- 
tigens in detail, we analyzed the frequencies  of human mH 
antigens that are recognized by an HLA-B35-restricted CTL 
clone using an acid elution method for peptides and sequencing 
of HLA-B35 genes. Moreover, the current study demonstrated 
a molecular mechanism for the presentation of human mH 
peptides by HLA class I molecules. 
Materials and Methods 
Cells.  PBLs  from 23 Japanese individuals  and 25 German indi- 
viduals with HLA-B35 were collected. HLA haplotypes of these 
individuals were serologically  determined. These PBLs were stimu- 
lated with PHA. PHA-induced  T cells were cultured in RPMI 1640 
medium with 10% FCS and 50 U/ml recombinant human IL-2, 
1 Abbreviation used in this paper: mH, minor histocompatibility. 
and the cells were used for CTL assays. EBV-transformed  cell lines 
from German individuals, EBV-transformed self-B cell line from 
a  recipient of HLA-identical renal grafts  (Pt  cells) (7), EBV- 
transformed B cell lines from a donor (Dn-2) (7), and Hmy2CIR 
(CIR) cells were maintained in RPMI 1640 medium with 10% 
FCS. T2 cells expressing HLA-B*3501 (T2-B*3501) were previ- 
ously generated (29), and they were cultured in RPMI 1640 medium 
with 10% FCS. 
Transfection of the HLA-B*3502 Gene into C1R Cells.  The HLA- 
B'3502 genomic gene was previously cloned (30). This gene was 
cotransfected with a hygromycin-resistance  gene into HLA-A, B 
null C1R cells as previously described (31). CIR cells expressing 
HLA-B*3502 (CIR-B*3502) were selected  by flow cytometry using 
SFR8-B6 anti-HLA-Bw6 mAb (32). C1R cells expressing  B'3501 
(CIR-B*3501) were previously generated (33). CIR-B*3502 and 
CIR-B*3501 cells were cultured in RPMI 1640 medium with 10% 
FCS and 0.15 mg/ml hygromycin B. 
Flow Cytometry  Analysis.  Approximately 5  x  105 cells, sus- 
pended in 50 ml of PBS with 2% FCS, were incubated with 50 
ml of appropriately diluted SFRS-B6 anti-HLA-Bw6  or 4D12 
anti-HLA-B5, B35 cross-reacting antigen mAb (34) for 30 rain 
on ice. After two washes with PBS containing 2% FCS, the cells 
were incubated with  50  ml  of FITC-conjugated F(ab')2 goat 
anti-mouse Ig (Silenus Laboratories, Hawthorne, Australia) at a 
dilution of 1:40 for 30 min on ice. The cells were washed three 
times with PBS containing 2% FCS, and the mean intensity of 
fluorescence  was measured  by a FACStar (Becton Dickinson, Moun- 
tain View, CA). 
CTL Clones.  Four  human mH antigen-specific,  HLA-B35-re- 
stricted CTL clones, NH-5.2, NH-5.3, NH-5.5, and NH-5.9, were 
previously  generated and characterized (7). These CTL clones were 
maintained by repeated stimulations with the EBV-transformed  B 
cell line Dn-2 at  1-wk intervals and feeding with RPMI  1640 
medium supplemented with 2 mM g-glutamine, 10% FCS, and 
50 U/ml human recombinant IL-2 every third day. 
CTL Assay.  Target  cells (5  x  10  s) were incubated for 60 or 
90 min with 100 #Ci of Na2SaCrO4 in PBS and washed three 
times with RPMI 1640 medium containing 10% FCS. Target cells 
(5  x  1@ per well) were added to serial dilutions of effector cells 
at E/T ratios of 4:1-0.5:1, and the mixtures were incubated for 
4 or 6 h at 37~  in 96-well round-bottom microtiter plates (Nunc, 
Roskilde, Denmark). The supematants were collected  and analyzed 
with a gamma counter. Spontaneous saCr release was determined 
by measuring the counts per minute in the supernatant in wells 
containing only target cells. The maximum release was determined 
by measuring the release of SlCr from target cells in the presence 
of 2.5% Triton X-100. The specific lysis was calculated using the 
following formula: percent specific lysis =  [(cpm~p -  cpmspn)/ 
(cpmm~ --  cpm,p,)] x  100, where cpm~p is the counts per minute 
in the supernatant in wells containing target and effector cells, 
cpmsp, is the spontaneous release, and cpm  ..... is the maximum 
release. 
Isolation and Characterization  of HLA-B35 cDNA  Clones.  Total 
cellular RNA was extracted from EBV-transformed cell lines by 
standard methods  (35). mRNA was  reverse transcribed using 
random hexamers  (first strand DNA synthesis  kit; Pharmacia  LKB 
Biotechnology  Inc., Piscataway,  NJ,). cDNA was then PCR ampli- 
fied with HLA-B  locus-specific  primers, as described (36). Amplified 
DNA was subcloned in the SalI/HindIII sites of pUC18. Recom- 
binant clones were identified by colony hybridization to an HLA 
class I cDNA probe, pHLA-2 (37). Double-stranded  DNA plasmids 
were sequenced  by the chain termination method using Sequenase 
2.0 (United States Biochemical  Corp., Cleveland, OH) and exon- 
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and was confirmed in four independent clones derived from each 
individual. 
Acid Extraction of Naturally Occurring Human mH Peptides  from 
EBV--transformed Cell Lines.  Cultured EBV-transformed cell lines 
and C1R-B*3501  cells (109) were homogenized in 0.1% (vol/vol) 
TFA solution and then sonicated for 30 s. The homogenates were 
ultracentrifuged for 30  min  (10,000  g).  These procedures were 
repeated for the pellets. Supernatants were loaded on a Sephadex 
G-25 column (Pharmacia) equilibrated with 0.1% TFA solution. 
Material of low molecular weight eluted in the column volume 
was collected, lyophilized, and separated on a Superpac Pep S reverse- 
phase HPLC column (Pharmacia) by forming a linear gradient of 
0.1% TFA in water and 0.1%  TFA in acetonitrile (60%  per 35 
min). Each 1-ml fraction was collected and lyophilized  for CTL assay. 
Acid Extraction of Naturally Occurring Human mH Peptides  from 
Purified HLA-B35 Subtype Molecules.  2  ￿  109 CIR.-B*3501  and 
EBV-transformed B cells expressing four HLA-B35 subtypes were 
lysed in 2 ml of 1.5% NP-40 detergent in 10 mM PBS containing 
1 mM PMSF,  10 mg/ml trypsin inhibitor A, 10 -S M pepstatin A, 
10 -5 M leupeptin, and 10 -4 M iodoacetamide. The resulting sus- 
pension was stirred for 30 rain at 4~  and centrifuged for 30 min 
(1,800 g). The resulting supernatant was incubated with CNBr- 
activated Sepharose CL4B beads (Pharmacia), to which 4D12 or 
W6/32 mAb had been covalently coupled. The sample was again 
rotated six times at 4~  to precipitate FILA class I molecules. After 
washing in 10 mM PBS containing 0.1% NP-40, loaded beads were 
subjected to 50 mM diethylamine (pH 11.5). Eluted sample were 
lyophilized, resolved in 2 ml of 0.1% TFA, and separated in a Su- 
perpac Pep S reverse-phase HPLC column. Each fraction (1 ml) was 
collected and lyophilized for CTL assay. 
CTL Assay.for B Cell Lines Stimulated with Isolated Human mH 
Peptides.  Dried HPLC fractions were dissolved in 200 #1 of PBS. 
50 #1 of this solution was added to 50 #1 of the medium containing 
5  x  103 StCr-labded B cell lines in round-bottom wells of a 96- 
well microplate. After incubation for 60 rain at 37~  100 #1 of 
the medium containing 2  x  l& CTL clones was added to yield 
a final volume of 200 #1 (4:1 E/T ratio). Plates were then incubated 
for 6 h at 370C. The supematants were collected and analyzed with 
a gamma counter. 
Results 
Recognition  of Human  mH Antigens on Cell Lines Derived 
from Japanese and German Individuals with HLA-B3 5 by HLA- 
Table  1.  Expression of Human  mH Antigens Presented by HLA-B35 on PHA-induced T  Cell Lines from the Japanese Population 
CTL clones 
Source of 
target cells  HLA type  NH-5.2  NH-5.3  NH-5.5  NH-5.9 
KaS  A24/A -  B35/B54  Cwl/Cwl0  54.8*  54.7  57.4 
KoE  A26.1/A11  B35/B46  Cw9/Cwll  56.3  57.1  60.5 
SuM  A2/A31  B35/B -  Cw9/Cw -  60.2  64.6  68.7 
SiR.  A2/A24  B35/B46  CwI1/Cw -  49.3  67.4  60.6 
MiN  A26.3/A26.4  B35/B52  Cw9/Cw-  26.9  40.8  31.3 
MuM  A11/A -  B35/B67  Cw7/Cw9  61.6  70.7  69.2 
OoT  A2/A24  B35/B61  Cw -/Cw  -  50.9  58.1  56.1 
KaO  A24/A26.3  B35/B61  Cw9/Cw -  53.1  73.4  60.5 
WaN  A24/A26.3  B35/B52  Cw9/Cw -  40.4  68.1  52.6 
SuR  A2/A26.1  B35/B54  Cwl/Cw9  46.6  70.2  58.2 
MaU  A24/A26.3  B35/B62  Cw9/Cw -  42.8  76.4  53.9 
NoH  A2/A -  B35/B62  Cw9/Cw -  45.9  67.9  56.7 
UsT  All/A26.3  B35/B -  Cw9/Cw -  69.7  68.0  72.0 
InT  A24/A33  B35/B48  Cw9/Cw -  61.1  65.2  59.1 
OnN  A2/A -  B35/B54  Cw9/Cw -  66.8  64.3  68.3 
TsH  A2/A26.4  B35/B39  Cw7/Cw -  68.4  63.9  74.3 
MuT  A2/A24  B35/B52  Cw9/Cw -  56.7  69.9  63.0 
MaS  A2/A33  B35/B44  Cw9/C4451  39.2  43.2  37.1 
MuU  A2/A26.3  B35/B -  Cw9/Cw-  57.9  61.6  61.5 
IsS  A24/A26.3  B35/B7  Cw7/Cw9  60.1  62.4  58.8 
MiT  A2/A31  B35/B51  Cw -/Cw  -  50.8  64.9  65.8 
Sak  A2/A24  B35/B51  Cw9/Cw-  47.1  58.7  62.3 
MiM  All/A26  B35/B51  Cwl/Cw9  64.6  73.3  67.0 
56.0 
65.7 
73.4 
65.6 
38.7 
73.1 
54.6 
56.3 
42.1 
58.1 
47.4 
52.9 
69.6 
56.1 
62.5 
64.2 
55.7 
33.4 
56.6 
54.1 
58.3 
53.3 
65.6 
" Percent specific lysis at a 1:1 E/T ratio.  More than 20%  of percent specific lysis was evaluated as positive killing (boldface). 
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Our previous study (7) showed that four mH antigen-specific, 
HLA-B*3501-restricted  CTL  clones  (NH-5.2,  NH-5.3, 
NH-5.5, and NH-5.9) killed B cell lines derived from all of 
five individuals with HLA-B35. These findings suggest that 
the human mH antigens recognized by these CTL clones are 
very well conserved among  Japanese or other populations and 
that only members of this family lack these antigens. To iden- 
tify the distribution of human mH antigens in populations, 
we examined the recognition by the CTL clones of a panel 
of cells derived from Japanese  and German individuals.  As 
shown in Table 1, four CTL clones killed all of 23 cell lines 
from Japanese individuals with HLA-B35. On the other hand, 
the CTL clones killed 19 of 25 cell lines from German Cau- 
casian individuals; they partially killed three cell lines (12405, 
13159, and 21254), but did not kill another three cell lines 
(18514, 20073,  and 22338) (Table 2). Taken together, these 
data suggest that the human mH antigens recognized by these 
four CTL clones may be less conserved within the Caucasian 
population than the Japanese  population, though they are 
very well conserved in the Japanese  population. 
It is speculated that poor recognition of the CTL clones 
for three cell lines (the CTL weakly sensitive cell lines) or 
lack of recognition of three cell lines (the CTL-resistant cell 
lines) may be due to low or even absent expression of HLA- 
B35 antigens on the cell lines, respectively. To exclude this 
possibility, we examined the surface expression of HLA-B35 
antigens on these cell lines by flow cytometry with 4D12 
anti-BS, B35 mAb. As shown in Table 3, all of the cell lines 
expressed HLA-B35. Mean intensities of fluorescence of cell 
lines 13159 and 19635 were higher than those of other cell 
lines expressing HLA-B35. This is explained by the fact that 
mAb 4D12 cross-reacts with HLA-B15 (34). The mean in- 
tensities of fluorescence of the other five cell lines (13.9 to 
29.0) were the same as those of six CTDsensitive cell lines 
(10.5 to 28.4).  These results  indicate that weak or lacking 
Table 2.  Expression of Human  mH Antigens  Presented by HLA-B35  on PHA-induced  T  Cell Lines from  the German Population 
Source  of 
target cells  HLA type 
CTL clones 
NH-5.2  NH-5.3  NH-5.5  NH-5.9 
83A2  A1/A11  B35/B7  Cw4/Cw7  71.2"  77.1  67.3 
M1202  A2/A3  B35/B39  Cw4/Cw -  59.6  74.5  61.2 
M1228  A3/A29  B35/B44  Cw4/Cw-  57.1  58.4  50.8 
22337  A2/A26  B35/B55  Cw3/Cw4  58.6  82.2  56.9 
22322  A1/A3  B8/B35  Cw4/Cw7  65.9  86.7  77.4 
12717  A2/All  B7/B35  Cw4/Cw7  56.2  69.5  51.1 
20058  A24/A29  B35/B44  Cw-/Cw-  74.4  100.0  71.6 
19635  A3/A68  B35/B35  Cw4/Cw4  74.7  91.9  89.2 
22358  A2/A-  B35/B39  Cw4/Cw7  83.9  100.0  81.1 
17772  A2/A3  B27/B35  Cw2/Cw4  48.9  79.0  58.4 
22780  A3/A-  B27/B35  Cw2/Cw4  66.4  78.3  72.5 
21142  A2/A24  B27/B35  Cwl/Cw4  52.0  100.0  51.1 
22008  A3/A-  B35/B44  Cw6/Cw-  65.3  61.1  73.3 
16213  A3/A -  B7/B35  Cw4/Cw7  82.8  57.3  51.7 
22339  A2/A24  B35/B44  Cw4/Cw5  67.0  41.7  43.6 
11985  A3/A24  B35/B44  Cw4/Cw5  70.3  82.2  61.3 
10476  A1/A3  B8/B35  Cw4/Cw7  72.5  58.7  56.4 
20072  A30/A68  B27/B35  Cw2/Cw4  82.9  70.4  71.7 
12893  A2/A24  B35/B49  Cw4/Cw -  80.5  100.0  100.0 
12405  A3/A28  B18/B35  Cw4/Cw -  18.5  29.5  15.1 
13159  A2/A24  B35/B62  Cw3/Cw-  16.5  18.8  11.9 
21254  A2/A3  B7/B35  Cw4/Cw7  9.8  14.6  8.6 
18514  A1/A3  B7/B35  Cw4/Cw -  -  1.3  0.7  -  1.0 
20073  A3/A32  B35/B64  Cw4/Cw8  -  1.0  -  0.9  -  1.7 
22338  A1/A24  B35/B41  Cw4/Cw-  -  0.2  0.1  -  1.7 
68.2 
58.6 
57.2 
46.0 
72.0 
63.6 
77.2 
83.5 
80.5 
58.0 
70.6 
48.2 
60.1 
67.7 
47.4 
84.4 
61.5 
66.3 
81.1 
17.9 
15.1 
6.9 
0.0 
-0.6 
-1.3 
* Percent specific lysis at a 1:1 E/T ratio. More than 20%  of percent specific lysis was evaluated as  positive killing (boldface). 
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EBV transformed Cell Lines 
mAb 
CTL  HLA-B 
Cell line  response  haplotype  4D12  -  * 
12405  W*  18,35  14.0  S  1.7 
13159  W  35,62  78.8  2.0 
21254  W  7,35  24.7  2.0 
18514  -  7,35  29.0  2.1 
20073  -  35,64  13.9  1.9 
22338  -  35,41  16.3  2.2 
11985  +  35,44  19.9  4.0 
12717  +  7,35  16.2  2.7 
19635  +  35,35  31.6  3.3 
20072  +  27,35  16.3  2.6 
21142  +  27,35  14.0  3.1 
22780  +  27,35  10.5  2.5 
Dn-2  +  35,38  28.4  2.0 
Pt  -  35,38  27.2  2.3 
" No primary antibody. 
Weak response of the CTL clones. 
S  Mean intensities of fluorescence. 
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Figure  1.  Recognition  by CTL clone  NH-5.5 of the CTL weakly  sen- 
sitive cell lines with different  incubation times. Killing activity  of CTL 
clone NH-5.5 for the CTL weakly sensitive  cell lines (12504, 13159, and 
21254), a self-B cell line (Pt), and a donor derived  cell line (Dn-2) was 
tested with incubation times of 4 (O) and 6 (Q) h. 
recognition by the CTL clones of these CTL weakly sensi- 
tive and CTL-resistant cell lines does not result from low or 
absent expression of HLA-B35 molecules. 
Three cell lines, 12405,  13159, and 21254,  were partially 
killed by four CTL clones with a 4-h incubation and an E/T 
ratio of 1:1. The killing of these cell lines was enhanced with 
a 6-h incubation (Fig.  1), suggesting that HLA-B35 mole- 
cules on these cell lines may present a small amount of the 
human mH peptide to CTL clones. 
Sequence of  HLA-B3 5 Genes in Three CTI.,resistant Cell Lines 
and Three CTL Weakly Sensitive Cell Lines.  It is speculated 
that the CTbresistant or weakly sensitive cell lines express 
HLA-B35 subtypes that are different from B'3501, since the 
recognition of four human mH CTL clones is restricted with 
B'3501 (11). To clarify this possibility, we attempted to clone 
cDNA encoding HLA-B35 from these cell lines, and the exons 
2-4 of the genes were sequenced. The sequence of the HLA- 
B35 genes derived from cell line 18514 was identical to that 
of HLA-B*3502 (30). The sequences of HLA-B35 genes de- 
rived from cell lines 20073 and 22338 differed from HLA- 
B'3501 by a single nucleotide substitution at codons 16 and 
156,  respectively. The glycine codon, GGC,  in B'3501  is 
replaced by the valine codon, GTC, in the gene from cell 
line 20073, whereas the leucine codon, CTG, in B'3501 is 
substituted by the arginine codon, CGG, in the gene from 
cell line 22338.  The novel HLA-B35 subtypes on cell lines 
20073 and 22338 have been designated as B'3507 and B'3508, 
respectively (38). The sequences of HLA-B35 genes derived 
from three cell lines,  12405,  13159,  and 21254,  were iden- 
2041  Beck et al. 
tical to that of HLA-B*3503. Polymorphic residues in these 
HLA-B35 subtypes are shown in Table 4. 
B'3502 differs from B'3501 by three amino acids at posi- 
tions  109,  114, and  116. Residues  114 and  116 are located 
on the floor of the/3 sheet, and the residue 109 is in the outer 
loop on the/3 sheet (Fig. 2). B'3503 (39), B'3507, and B'3508 
differ from B'3501 only by a single amino acid substitution 
at residues 116, 16, and 156, respectively. Residue 156 is a 
peptide-binding site in the o~2 helix, and residue 16 is in the 
outer loop of the B  sheet (Fig.  2). 
Table 4.  Polymorphic  Residues in HLA-B35 Subtypes of Six 
Cell Lines 
Substituted  amino 
acid residue 
Cell line  16  109  114  116  156  Allele 
Gly  Leu  Asp  Ser  Leu  B'3501 
18514  -*  Phe  Asn  Tyr  -  B'3502 
20073  Val  ....  B~3507 
22338  ....  Arg  B~3508 
12405, 13159,  -  -  -  Phe  -  B'3503 
21254 
* Dashes indicate identity with HLA-B*3501. )86  CxO 
Figure 2.  Location  of the amino  acid  substitutions  in HLA-B*3501  and 
other HLA-B35 subtypes. HLA-B*3501  differs  from  HLA-B'3502  by sub- 
stitutions at residues 109, 114, and 116 (l~), from  HLA-B'3503  by substi- 
tution at residue 116 (&), from HLA-B'3507 by substitution  at residue 
16 (O), and from HLA-B*3508 by substitution at residue 156 (11). 
Recognition of Human mH Antigens on CIR Cells Transfected 
with the HLA-B*3502 Cene.  Our previous study (7) showed 
that four human mH antigen-specific, HLA-B*3501-restricted 
CTL clones can kill C1R cells transfected with the HLA- 
B'3501 gene (C1R-B*3501), but not untransfected C1R cells. 
These findings indicated that C1R cells possess the human 
mH antigens presented by HLA-B*3501  molecules.  To in- 
vestigate the presentation of human mH antigens by HLA- 
B'3502 molecules, the HLA-B*3502 gene was transfected 
into CIR cells, and the transfectant highly expressing HLA- 
B'3502 (CIR-B*3502) was selected by flow cytometry using 
SFR8-B6 anti-Bw6 mAb. As shown in Fig. 3, four human 
mH antigen-specific  CTL clones killed C1R-B*3501 cells but 
not ClP,-B*3502 cells.  These results indicated that HLA- 
B'3502 molecules cannot present human mH antigens to the 
T  cell clones. 
Binding of the Human mH Peptide to HLA-B35 Antigens on 
Three CTL-resistant  Cell Lines and Three CTL  I,  Veakly Sensi- 
tive Cell Lines.  Our recent studies showed that four human 
mH  antigen-specific, HLA-B*3501-restricted CTL clones 
recognize the human mH peptides presented by HLA-B*3501 
molecules (11, 12, 29). Therefore, the results of experiments 
using CIR-B*3502 and the sequence data of the HLAoB35 
gene in CTL-resistant cell lines and CTL weakly sensitive 
cell lines  suggest that B'3502 molecules in the 18514 cell 
line and B'3508 in the 22338 cell line do not bind the human 
mH peptides, whereas B'3503 molecules in three CTL weakly 
sensitive celt lines bind a relatively small amount of the human 
mH peptides.  To clarify this possibility, we investigated di- 
rect binding of the human mH peptides to HLA-B35 sub- 
type molecules on these cell lines. Naturally occurring human 
mH peptides were isolated by reverse-phase HPLC from HLA- 
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Figure 3.  Recognition  by HLA-B*3501-restricted, human mH an- 
tigen-specific CTL clones  of CIR-B*3502 cells. Killing  activity  of NH- 
5.2 (A), NH-5.3 (B), NH-5.5 (C), and NH-5.9 (D) for CIR-B*3501 (O), 
CIR.-B*3502 (ll), or untransfected  C1R (U]) cells was tested. Surface  ex- 
pression of HLA-B35 antigens  on C1R-B'3501, C1R-B*3502, and C1R 
cells was examined  by flow  cytometry  using  mAb SFR8-B6. Mean  inten- 
sities of fluorescence  of C1R-B*3501, C1R-B'3502, and C1R calls were 
188.3, 243.8, and 6.7, respectively. 
B'3501 molecules that were purified from C1R-B*3501 cells. 
The HPLC fraction containing human mH peptides was de- 
tected using four CTL clones as previously described (11) and 
was used as the source of human mH peptides.  The cells ex- 
pressing HLA-B35 subtypes were cultured at 26~  overnight 
and then used as target cells for four CTL clones after stimu- 
lation with human mH peptides.  As shown in Fig.  4, the 
18514 cell line expressing B'3502 molecules and the 22338 
cell line expressing B'3508 molecules stimulated with human 
mH peptides were not killed by the CTL clones,  whereas 
20073 cells expressing B'3507 molecules loaded with human 
mH peptides were killed by the CTL clones.  Three CTL 
weakly sensitive cell lines (12405, 13159, and 21254) expressing 
B'3503 molecules stimulated with the human mH peptides 
were more effectively killed by the CTL clones than were 
unstimulated cell lines.  These results indicate that B'3502 
and B'3508 molecules cannot bind the human mH peptides, 
whereas B'3503 and B'3507 molecules can bind the same 
amount of the human mH peptides as B'3501.  Moreover, 
since 20073 cells were not killed by the CTL clones,  these 
results together suggest that the specific human mH pep- 
tides are not produced in the 20073 cell line expressing B'3507. 
Isolation of  Naturally Occurring Human mH Peptides  from CTL 
resistant Cell Lines and CTL Weakly Sensitive Cell Lines,  We 
attempted to isolate the naturally occurring human mH pep- 
tides from HLA-B35 subtype molecules on CTL-resistant cell 
lines and CTL weakly sensitive cell lines by acid elution. Rel- 
atively low molecular mass material extracted by acid elution 
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Figure 4.  Enhancement  of T cell recognition  for the cell lines expressing HLA-B35 subtypes  by loading with human mH peptides isolated from 
HLA-B*3501 molecules purified form CIR-B*3501 cells, s~Cr-labeled  B cell lines were incubated with fraction 31, which contains the human mH 
peptides isolated from HLA-B*3501  molecules derived from 2.5  x  10  s C1R-B*3501 cells. Killing activity by four CTL clones was tested. 
from the cell line lysates was separated by reverse-phase HPLC. 
Fractions 29-32 were tested for recognition of the NH-5.5 
clone using Pt cells as the target, since the human mH pep- 
tides that the CTL clones recognized were isolated in frac- 
tion 30 or 31 (11). A small amount of the human mH peptides 
was detected in fraction 30 from extracts of the CTL-resistant 
cell line 22338, whereas no human mH peptides were iso- 
lated from extracts of other cell lines (Fig.  5).  Since  three 
CTL weakly sensitive cell lines were partially killed by the 
CTL clones, it is suspected that the amounts of peptides iso- 
lated from these cell lines are too small to be detected by the 
CTL assay using Pt cells as target cells. Therefore, we used 
HLA-B*3501-transfected T2 cells (T2-B*3501) as target cells 
in the assay in order to detect a small amount of the human 
mH peptides because the T2 transfectants express many empty 
HLA-B35 molecules. Pt and T2-B*3501 cells were stimu- 
lated with titrated fraction 30 containing the human mH pep- 
tides from CIR-B'3501 cells and then tested by using the 
NH-5.5 clone. As shown in Fig. 6, the capacity of the CTL 
clone to detect the human mH peptides was enhanced 10- 
fold when T2-B*3501 cells were used as target cells. 
Fractions 29-32 were again tested for recognition by the 
NH-5.5 clone using T2-B*3501 cells (Fig.  7).  The human 
mH peptides were detected in fraction 31 from three CTL 
weakly sensitive cell lines as well as the 18514 and 22338 cell 
lines. In contrast, no human mH peptides were isolated from 
the 20073 cell line. These results demonstrated that only the 
20073 cell line does not possess  human mH antigens. 
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Figure  5.  Isolation  of naturally  occurring human mH peptides from 
cell lines expressing HLA-B35 subtypes. Fraction 28-33 derived from each 
cell line expressing the HLA-B35 subtypes were tested for recognition by 
CTL clone NH-5.5 (e) and for cytotoxicity without CTL clone NH-5.5 
(O) by using Pt cells as target cells. u~ 
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Figure 6.  Enhancement  of sensitivity to  detect  naturally  occurring 
human mH peptides by using T2-B*3501 cells as target cells. Fraction 
31 derived from  109 CIR-B*3501  cells was dissolved in 200/zl of PBS 
and diluted.  50 #1 of each diluted sample was tested for the recognition 
by CTL clone NH-5.5 using T2-B*3501 (0) and Pt (O) cells. Percent 
specific lysis for T2-B*3501 cells loaded without peptide (I) and that 
for Pt cells loaded without peptide ([-]) are m0%. 
Isolation of Naturally Occurring Human  mH Peptides from 
HLA-B35 Subtype Molecules Purified from CTLresistant Cell 
Lines and CTL Weakly Sensitive Cell Lines.  The human mH 
peptides recognized by the NH-5.5 clone were isolated from 
whole-cell extract from five cell lines expressing HLA-B*3502, 
B'3503, or B'3508 (Fig. 7). This does not demonstrate di- 
rect isolation of the specific human mH peptides from these 
HLA-B35 subtype molecules. Therefore, we attempted to iso- 
late the specific human mH peptides from purified HLA-B35 
subtype molecules. HLA-B35 molecules were isolated from 
six cell lines expressing HLA-B35 sybtypes as well as from 
Pt and Dn-2 cells using Sepharose beads coupled with 4D12 
anti-B5, B35 mAb. Peptides bound to these HLA-B35 mol- 
ecules were isolated by reverse-phase  HPI.C after purified HLA- 
B35 molecules were resolved in 0.1% TFA solution. Frac- 
tions 29-32 were tested for recognition by the NH-5.5 clone 
using T2-B*3501  cells as target cells (Fig. 8). The specific 
human mH peptides were again isolated from HLA-B*3502, 
B'3503, and B'3508 molecules purified from the cell lines 
expressing  these HLAoB35  subtypes.  The amount of the 
specific peptides isolated from these subtype molecules was 
significantly smaller than that that from HLA-B*3501 mole- 
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Figure 7.  Detection  of naturally occurring human mH peptides de- 
rived from whole-cell lysates from cell lines expressing HLA-B35 subtypes 
by using T2-B*3501 cells as target cells. The same fractions shown in Fig. 
5 were tested for the recognition  by CTL clone NH-5.5 (0) and cytotox- 
icity without the CTL clone NH-5.5 (O) using T2-B*3501 cells as target 
cells. 
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Figure 8.  Detection  of naturally occurring human mH peptides iso- 
lated from HLA-B35 subtype molecules purified from cell lines expressing 
HLA-B35 subtypes. The same fractions shown in Fig. 5 were tested for 
recognition by CTL clone NH-5.5 (Q) and cytotoxicity without CTL 
clone NH-5.5 (O) using T2-B*3501 cells as target cells. 
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B'3502,  B'3503,  and B'3508  molecules, are able to bind 
a small amount of the peptides recognized by the NH-5.5 
clone. Similarly, the peptides recognized by the NH-5.2, NH- 
5.3, and NH-5.9 clones were isolated in the same HPLC frac- 
tion from the same cell lines that yielded the peptides recog- 
nized by done NH-5.5 (Table  5). Taken  together, these findings 
indicate that the human mH peptides recognized by the CTL 
clones bind to HLA-B*3502, B'3503, and B'3508 molecules 
in the cell lines expressing these HLA-B35 subtype molecules. 
Discussion 
Three CTL weakly sensitive cell lines carry HLA-B*3503 
molecules that differ from HLA-B*3501 by a single amino 
acid substitution at position 116 on the floor of the peptide- 
binding groove. Since residue 116 is located on the bottom of 
the F pocket (40, 41), it is suspected that the substitution 
of phenylalanine for serine at this position reduces the binding 
of human mH peptides.  The reduction in the binding of 
human mH peptides may cause weak recognition of the cells 
expressing HLA-B*3503 by the specific CTL clones. In fact, 
the current study demonstrated that a small amount of the 
specific peptides is eluted from the cells carrying HLA-B*3503. 
In contrast,  the HLA-B*3503 molecules appear to have the 
ability to bind effectively the human mH peptides  on the 
cell surface  because the killing of ceUs expressing  HLA-B*3503 
by the CTL clone is enhanced by the stimulation of human 
mH peptides from C1R-B*3501 cells. These results imply 
that HLA-B*3503 molecules bind other self-peptides more 
effectively than the specific human mH peptides. 
HLA-B*3502 differs from HLA-B*3501 by 3 amino acid 
substitutions  at positions  109, 114, and 116 on the B sheet. 
Since the CTL clones cannot kill C1R cells expressing  B'3502, 
it is speculated that HLAoB*3502 molecules cannot bind the 
human mH  peptides.  The substitution  of asparagine for 
asparatic acid at residue 114 and tyrosine for serine at residue 
116 may affect the binding of the human mH peptides be- 
cause residues 114 and  116 are located on the floor of the 
peptide-binding  groove and are facing the E and F pockets, 
respectively (40, 41). The current study demonstrated that 
a small amount of human mH peptides is duted from HLA- 
B'3502 molecules purified from cell line 18514 expressing 
this subtype. On the other hand,  recognition by the CTL 
clone of cell line 18514 was not induced by stimulation with 
human mH peptides eluted from B'3501 molecules. These 
results raise two possibilities: (a) HLA-B*3502 molecules can 
bind a small amount of human mH peptide that is not enough 
for the recognition by the CTL clones, or (b) the substitu- 
tions at positions 114 and 116 induce a conformational change 
of the human mH peptides bound to the HLA class I mole- 
cules, resulting in a lack of recognition by the CTL clones. 
However, it is difficult to explain the lack of recognition of 
CTL clones for the cell line 18514 expressing HLA-B*3502 
by the former hypothesis alone, since the amount of human 
mH peptides eluted from B'3502 molecules purified from 
cell line 18514 is almost the same as that from B'3503 mole- 
cules purified from the cell lines expressing HLA-B*3503 
(12405, 13159, and 21254). 
HLA-B *  3508 differs from HLA-B*  3501 by a single amino 
acid substitution at position  156. Since this residue is one 
of the peptide-binding sites facing the E pocket, it is assumed 
that the substitution of arginine for leucine affects  the binding 
of human mH peptides. The current study shows that the 
amount of the human mH peptides duted from B'3508 mol- 
ecules purified from the 22338 cell line is less than that from 
B'3501  molecules purified from Dn-2 cells. However, the 
amount of human mH peptides bound to HLA-B*3508 mol- 
ecules seems to be sufficient for the recognition by the CTL 
clones, since it is significantly more than that from B'3503 
molecules purified from the cell lines expressing this B35 sub- 
type that were partially killed by the CTL clones. A previous 
Table 5.  Isolation of Human mH Peptides Recognized by Four Human roll-specific CTL Clones 
from Purified HLA-B35 Subtype Molecules 
HPLC fraction 
NH5.2  NH5.3  NH5.5  NH5.9 
Cdl line  HLA-B35  30  31  30  31  30  31  30  31 
18514  B'3502  0*  11.2  0  15.3  0  9.9  0  13.2 
12405  B'3503  0  9.5  0  10.1  0.1  11.2  0  9.5 
13159  B'3503  14.8  15.2  15.6  16.8  11.7  13.8  20.2  22.4 
21254  B'3503  6.5  8.2  9.2  9.4  7.2  7.2  7.4  7.6 
20073  B'3507  0  0  0  0  0.3  0  0  0 
22338  B'3508  38.4  36.1  37.7  32.4  32,5  31.5  35.5  31.3 
DN-2  B'3501  50.3  41.1  69.2  60.2  64.9  51.7  65.4  58.3 
Pt  B'3501  0  0  0  0  0  0  0  0 
* Percent specific lysis. 
2045  Beck et al. study using an HLA-A2 mutant at position 156 (42) demon- 
strated that 24 of 25 HLA-A2-restricted,  influenza virus ma- 
trix peptide-specific CTL lines could not recognize HLA-A2 
mutant at residue 156 loaded with the peptide, whereas one 
CTL line recognized it. This study suggested that the amino 
acid substitution at residue 156 of the HLA-A2 molecule affects 
the recognition by the specific CTL clones but does not in- 
hibit binding of the peptide to the HLA class I molecules. 
The current study together with  a previous  study using 
HLA-A2 mutant suggests that the substitution at residue 156 
changes the conformational structure of the peptides bound 
to the HLA class I molecules, resulting in a lack of recogni- 
tion of the CTL clones. 
We recently demonstrated that the substitution of glutamic 
acid for valine at residue 152 of HLA-B*3501 does not affect 
the binding of the human mH peptides recognized by CTL 
clones NH-5.2, NH-5.3, NH-5.5, and NH-5.9, but it does 
abrogate recognition by these CTL clones (29). Since residue 
152 is also one of the residues forming the E pocket, it sup- 
ports the idea that the substitution  at  the position  of the 
ot helix forming the E pocket changes the conformational 
structure of the human mH peptides bound to the HLA class 
I molecules. Moreover, the substitution of asparagine for 
asparaginic acid at residue 114 facing the E pocket and that 
of tyrosine for serine at residue 116 facing the F pocket seem 
to change the conformational structure of the human mH 
peptides bound to HLA-B35 molecules.  The amount of  human 
mH peptide bound to HLA-B*3502 molecules purified from 
the 18514 cell line is more than that bound to HLA-B*3503 
molecules  purified from three CTLs weakly sensitive  cell lines, 
whereas  the CTL  clone  partially  killed  PBLs expressing 
B'3503 but not those expressing B'3502.  Taken together, 
these observations of HLA-B*3502 and B'3508 suggest that 
T cells recognize a conformational structure of the human 
mH peptides bound to HLA-B35 molecules. 
HLA-B*3507 differs from B'3501 by a single amino acid 
substitution at position  16.  It is thought that this residue 
hardly affects peptide binding because residue 16 is on the 
outer loop of the B sheet. Therefore, it is assumed that cell 
line 20073 expressing  HLA-B*3507 molecules  does not possess 
the human mH antigens containing the specific epitope rec- 
ognized by the CTL clones. Indeed, the current study showed 
that the specific human mH peptides are not isolated from 
this cell line, whereas HLA-B*3507 molecules can bind the 
specific peptides. 
In this study, we demonstrated that the human mH pep- 
tides recognized by four CTL clones are presented by HLA- 
B35 molecules in all 23 Japanese individuals and in 24 of 25 
German individuals. Since there is no difference in recogni- 
tion by these CTL clones for a panel ofceUs expressing HLA- 
B35 and Pt cells loaded with the peptides eluted from the 
cells expressing HLA-B35 subtypes, it is suspected that these 
CTL clones recognize a single peptide. However, it will be 
confirmed only by identification of the peptides recognized 
by four CTL clones. Further identification of the peptides 
recognized by four CTL clones is necessary to darify the 
number of human mH peptides recognized by these CTL 
clones. The current study demonstrated that at least one 
human mH antigen is conserved in the Japanese and German 
populations. 
Since human mH antigens are recognized by T cells but 
not by antibodies, their polymorphism was studied only in 
the specific T cells. This study showed that five of six cell 
lines that are not killed by the CTL clones possess the human 
mH peptides. Thus, a simple analysis using killing activity 
by CTL clones cannot reveal the frequency of a human mH 
antigen in the population.  Analyses of HLA subtypes and 
human mH peptides are also required to estimate the fre- 
quency of human mH antigens in detail. We showed here 
that only 1 of 25 German people and 23 Japanese people lacks 
the human mH antigen containing the specific T cell epi- 
topes. This indicates that the human mH antigens are con- 
served  beyond race. The current study also demonstrated that 
HLA-B'3501-restricted, human mH antigen-specific CTL 
clones failed to recognize human mH peptides presented by 
other HLA-B35 subtype molecules. This indicates that pre- 
cise typing of HLA subtype is particularly required in bone 
marrow transplantation  in which incompatibility of human 
mH antigens induces graft rejection  and graft versus host 
disease. 
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